SLC5A2 and type 2 diabetes mellitus: The ongoing, randomised, pragmatic trial (DECIDE; NCT02616666) aims to evaluate the comparative effectiveness between the SGLT-2 inhibitor dapagliflozin and standard of care over 2 years in patients with T2D, and should provide further data on this therapeutic class [57].